Raquel Perez-Lopez1,2, Matthew D. Blackledge1,2, Joaquin Mateo1,2, David J. Collins1,2, Veronica A. Morgan1,2, Alison MacDonald1,2, Diletta Bianchini1,2, Zafeiris Zafeiriou1,2, Pasquale Rescigno1,2, Michael Kolinsky1,2, Daniel Nava Rodrigues1,2, Helen Mossop1, Nuria Porta1, Emma Hall1, Martin O. Leach1,2, Johann S. de Bono1,2, Dow-Mu Koh1,2, and Nina Tunariu1,2
We hypothesized that changes in the median apparent diffusion
coefficient (mADC) and volume of bone metastases (BM), quantified by whole body
(WB) diffusion-weighted imaging (DWI), are response biomarkers in metastatic castration-resistant prostate cancer (mCRPC).
21 patients completed WB-DWI at baseline and after 12 weeks of treatment
in a sub-study within a clinical trial of olaparib in mCRPC, performed on a
1.5-T Siemens Avanto scanner. Four different segmentation techniques were explored
including axial skeleton analyses and simpler methods including 5 target
lesions.
Changes in mADC and volume of BM associated with
response to therapy. The simplified approach also showed promising results,
warranting further evaluation.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Click here for more information on becoming a member.
